Aeluma (ALMU) 10-Q 11 Feb 25 2025 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Dec. 31, 2024	Feb. 07, 2025
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Amendment Flag	false
Document Period End Date	Dec. 31, 2024
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	Q2
Entity Information [Line Items]
Entity Registrant Name	AELUMA, INC.
Entity Central Index Key	0001828805
Entity File Number	000-56218
Entity Tax Identification Number	85-2807351
Entity Incorporation, State or Country Code	DE
Current Fiscal Year End Date	--06-30
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	27 Castilian Drive
Entity Address, City or Town	Goleta
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	93117
Entity Phone Fax Numbers [Line Items]
City Area Code	(805)
Local Phone Number	351-2707
Entity Listings [Line Items]
Title of 12(b) Security	None
No Trading Symbol Flag	true
Entity Common Stock, Shares Outstanding		12,247,481

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2024	Jun. 30, 2024
Current assets:
Cash and cash equivalents	$ 3,063,059	$ 1,291,072
Accounts receivable	1,324,632	60,004
Deferred compensation	6,171	20,133
Prepaids and other current assets	136,307	21,637
Total current assets	4,530,169	1,392,846
Property and equipment:
Equipment	1,572,291	1,531,494
Leasehold improvements	546,864	546,864
Accumulated depreciation	(809,436)	(608,630)
Property and equipment, net	1,309,719	1,469,728
Intangible assets	5,333	6,833
Right of use asset - facility	899,623	961,626
Other assets	13,014	13,014
Total assets	6,757,858	3,844,047
Current liabilities:
Accounts payable	182,932	317,237
Accrued expenses and other current liabilities	172,414	180,706
Lease liability, current portion	133,460	128,743
Total current liabilities	488,806	626,686
Lease liability, long term portion	873,276	941,200
Derivative liabilities	5,048,174
Convertible notes (Note 3)	1,379,690
Total liabilities	7,789,946	1,567,886
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value: 10,000,000 authorized, and none issued and outstanding at December 31, 2024 and June 30, 2024
Common stock, $0.0001 par value: 50,000,000 shares authorized, and 12,242,481 and 12,817,500 shares issued and outstanding at December 31, 2024 and June 30, 2024	1,224	1,218
Additional paid-in capital	16,215,492	15,899,304
Accumulated deficit	(17,248,804)	(13,624,361)
Total stockholders’ equity	(1,032,088)	2,276,161
Total liabilities and stockholders’ equity	$ 6,757,858	$ 3,844,047

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2024	Jun. 30, 2024
Statement of Financial Position [Abstract]
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	12,242,481	12,817,500
Common stock, shares outstanding	12,242,481	12,817,500

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Income Statement [Abstract]
Revenue	$ 1,612,519	$ 262,992	$ 2,093,254	$ 295,392
Operating expenses:
Cost of revenue	584,549	136,767	899,124	151,906
Research and development	268,061	651,099	669,135	1,485,968
General and administrative	370,311	603,925	866,777	1,269,028
Total operating expenses	1,222,921	1,391,791	2,435,036	2,906,902
Income (loss) from operations	389,598	(1,128,799)	(341,782)	(2,611,510)
Other income (expense):
Interest income	101	279	203	681
Amortization of discount on convertible notes	(283,043)		(427,819)
Changes in fair value of derivative liabilities	(3,001,480)		(2,855,045)
Total other income (expense), net	(3,284,422)	279	(3,282,661)	681
Loss before income tax expense	(2,894,824)	(1,128,520)	(3,624,443)	(2,610,829)
Income tax expense
Net loss	$ (2,894,824)	$ (1,128,520)	$ (3,624,443)	$ (2,610,829)
Loss per share - basic (in Dollars per share)	$ (0.24)	$ (0.09)	$ (0.3)	$ (0.21)
Loss per share - diluted (in Dollars per share)	$ (0.24)	$ (0.09)	$ (0.3)	$ (0.21)
Weighted average common shares outstanding - basic (in Shares)	12,212,403	12,167,930	12,195,415	12,418,579
Weighted average common shares outstanding - diluted (in Shares)	12,212,403	12,167,930	12,195,415	12,418,579

Consolidated Statement of Stock

Consolidated Statement of Stockholders’ Equity (Unaudited) - USD ($)	Common Stock	Additional Paid-in capital	Accumulated Deficit	Total
Balance at Jun. 30, 2023	$ 1,282	$ 15,171,074	$ (9,062,066)	$ 6,110,290
Balance (in Shares) at Jun. 30, 2023	12,817,500
Stock options exercised (in Shares)
Repurchase of common stock	$ (65)	(3,936)		$ (4,001)
Repurchase of common stock (in Shares)	(649,570)
Stock-based compensation		376,496		376,496
Net loss			(2,610,829)	(2,610,829)
Balance at Dec. 31, 2023	$ 1,217	15,543,634	(11,672,895)	3,871,956
Balance (in Shares) at Dec. 31, 2023	12,167,930
Balance at Sep. 30, 2023	$ 1,217	15,407,715	(10,544,375)	$ 4,864,557
Balance (in Shares) at Sep. 30, 2023	12,167,930
Stock options exercised (in Shares)
Stock-based compensation		135,919		$ 135,919
Net loss			(1,128,520)	(1,128,520)
Balance at Dec. 31, 2023	$ 1,217	15,543,634	(11,672,895)	3,871,956
Balance (in Shares) at Dec. 31, 2023	12,167,930
Balance at Jun. 30, 2024	$ 1,218	15,899,304	(13,624,361)	2,276,161
Balance (in Shares) at Jun. 30, 2024	12,178,424
Stock options exercised	$ 6	(6)
Stock options exercised (in Shares)	62,327			155,666
Stock warrants exercised
Stock warrants exercised (in Shares)	1,730
Stock-based compensation		316,194		316,194
Net loss			(3,624,443)	(3,624,443)
Balance at Dec. 31, 2024	$ 1,224	16,215,492	(17,248,804)	(1,032,088)
Balance (in Shares) at Dec. 31, 2024	12,242,481
Balance at Sep. 30, 2024	$ 1,218	16,066,395	(14,353,980)	1,713,633
Balance (in Shares) at Sep. 30, 2024	12,178,424
Stock options exercised	$ 6	(6)
Stock options exercised (in Shares)	62,327			155,666
Stock warrants exercised
Stock warrants exercised (in Shares)	1,730
Stock-based compensation		149,103		149,103
Net loss			(2,894,824)	(2,894,824)
Balance at Dec. 31, 2024	$ 1,224	$ 16,215,492	$ (17,248,804)	$ (1,032,088)
Balance (in Shares) at Dec. 31, 2024	12,242,481

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Operating activities:
Net loss	$ (3,624,443)	$ (2,610,829)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of deferred compensation	13,962	18,938
Stock-based compensation expense	316,194	376,496
Depreciation and amortization expense	202,306	131,783
Amortization of discount on convertible notes	427,819
Changes in fair value of derivative liabilities	2,855,045
Changes in operating assets and liabilities:
Change in accounts receivable	(1,264,628)	(3,753)
Change in prepaids and other current assets	(114,670)	(135,704)
Change in accounts payable	(134,305)	(298,974)
Change in accrued expenses and other current liabilities	(9,496)	41,698
Net cash used in operating activities	(1,332,216)	(2,480,345)
Investing activities:
Purchase of equipment	(40,797)	(164,290)
Net cash used in investing activities	(40,797)	(164,290)
Financing activities:
Repurchase of common stock		(4,001)
Proceeds from convertible notes issuance	3,145,000
Net cash provided by (used in) financing activities	3,145,000	(4,001)
Net change in cash	1,771,987	(2,648,636)
Cash, beginning of period	1,291,072	5,071,690
Cash, end of period	$ 3,063,059	$ 2,423,054

The Company

The Company	6 Months Ended
	Dec. 31, 2024
The Company [Abstract]
The Company	Note 1 – The Company Aeluma develops novel optoelectronic and electronic devices for sensing, communication, and computing applications. Aeluma has pioneered a technique to produce semiconductor materials and chips using high-performance compound semiconductors on large diameter substrates that are commonly used to manufacture mass market microelectronics. This enables cost-effective manufacturing of high-performance photodetectors and photodetector arrays for imaging applications in mobile devices, as well as other applications. Aeluma’s technology is broadly applicable across mobile, automotive, AI, defense & aerospace, communication, AR/VR, high-performance computing, and quantum computing. Aeluma is based in Goleta, California, where the Company operates in a 9,000 sq. ft. facility with a state-of-the-art R&D/manufacturing cleanroom and access to world-class rapid prototyping capabilities. The facility houses unique equipment for scalable manufacturing. Aeluma also partners with production-scale fabrication foundries and packaging companies. Aeluma maintains extensive patent protection and trade secrets that relate to its materials, manufacturing technology and applications. Going Concern The Company incurred a net loss of $3,624,443 and $2,610,829 for the six months ended December 31, 2024 and 2023, respectively, and has accumulated deficit of $17,248,804 at December 31, 2024. In addition, the Company is in the research and development stage and has generated limited revenue to date. In order to support its operations, the Company will require additional infusions of cash from the sale of equity instruments or the issuance of debt instruments, or the commencement of profitable revenue generating activities. If adequate funds are not available or are not available on acceptable terms, the Company’s ability to fund its operations, develop or enhance its sensors in the future or respond to competitive pressures would be significantly limited. Such limitations could require the Company to curtail, suspend or discontinue parts of its business plan. These conditions raise doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”), which contemplate continuation of the Company as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that could result from the outcome of this uncertainty. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Dec. 31, 2024
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements have been presented in accordance with GAAP. The summary of significant accounting policies presented below is designed to assist in understanding the Company’s financial statements. Such financial statements and accompanying notes are the representations of the Company’s management, who is responsible for the Company’s integrity and objectivity. This Quarterly Report on Form 10-Q for the quarter ended December 31, 2024, should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended June 30, 2024. The accompanying consolidated financial statements and footnotes have been condensed and therefore do not contain all disclosures required by GAAP. The interim financial data are unaudited; however, in the opinion of Aeluma, Inc., the interim data include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Results for interim periods are not necessarily indicative of those to be expected for the full year. Use of Estimates and Assumptions The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported consolidated financial statements. Cash and Cash Equivalents The Company considers cash in banks, deposits in transit, and highly liquid debt instruments purchased with original maturities of three months or less to be cash and cash equivalents. Concentration of Risk The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company’s accounts are insured by the FDIC but at times may exceed federally insured limits. Convertible Debt Instruments The Company evaluates agreements, including any convertible debt instruments to determine if those agreements or any embedded components of those agreements qualify as derivative financial instruments to be separately accounted for in accordance with FASB ASC Topic 815 Derivatives and Hedging 815” Fair Value of Financial Instruments As defined in Financial Accounting Standards Board (“FASB”) ASC Topic No. 820, “Fair Value Measurements and Disclosures” (“ASC 820”), fair value is the price that would be received to sell an asset or paid to transfer the liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses the market or income approach. Based on this approach, the Company utilizes certain assumptions about the risk inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based on the observability of the inputs used in the valuation techniques, the Company is required to provide the following information according to the fair value hierarchy. The fair value hierarchy ranks the quality and the reliability of the information used to determine fair values. As a basis for considering these assumptions, ASC 820 defines a three-tier value hierarchy that prioritizes the inputs used in the valuation methodologies in measuring fair value. Level 1 – Unadjusted quoted prices in active, accessible market for identical assets or liabilities Level 2 – Other inputs that are directly or indirectly observable in the marketplace Level 3 – Unobservable inputs which are supported by little or no market activity The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The carrying values of the Company’s cash, accounts receivable, accounts payable, accrued expenses and other current liabilities approximate their fair value due to the relatively short maturity of these items. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. For recurring fair value measurement categorized within Level 3 assets and liabilities include those whose value is determined using market standard valuation technique described below. When observable inputs are not available, the market standard techniques for determining the estimated fair value of certain securities that trade infrequently, and therefore have little transparency, rely on inputs that are significant to the estimated fair value and that are not observable in the market or cannot be derived principally from or corroborated by observable market data. Management believes these inputs are based on assumptions deemed appropriate given the circumstances and consistent with what other market participants would use when pricing similar assets and liabilities. The Company’s embedded derivatives are classified in Level 3 using Black-Scholes option-pricing model since their values include significant unobservable inputs. The derivative liabilities are recognized at fair value on a recurring basis at December 31, 2024 and are Level 3 measurements. There have been no transfers between levels. Fair Value of Embedded Derivatives Beginning balance at July 1, 2024 $ - New derivative liabilities 2,193,129 Change in fair value of derivative liabilities 2,855,045 Ending balance at December 31, 2024 $ 5,048,174 The fair value of the embedded derivatives in our convertible notes at the balance sheet date were valued using the Black-Scholes option-pricing model with the following assumptions: December 31, Stock price $ 7.65 Expected volatility 128.3 % Expected term 1.5 years Dividend yield 0.00 % Risk-free interest rate 4.21 % Property and Equipment Property, equipment and leasehold improvements are reported at historical cost, net of accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the less of the remaining lease term or the estimated useful life of the improvements. Repairs and maintenance to these assets are charged to expenses as incurred; major improvements enhancing the function and/or the asset’s useful life are capitalized. When items are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gains or losses arising from such transactions are recognized. Intangible Assets Intangible assets are associated with the Aeluma.com domain name and are amortized on a straight-line basis over 10 years. Revenue Recognition The Company follows a five-step approach for recognizing revenue, consisting of the following: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to the performance obligations in the contract; and (5) recognizing revenue when, or as, the entity satisfies a performance obligation. Sales and other taxes the Company collects concurrent with revenue-producing activities are excluded from revenue. Incidental items that are immaterial in the context of the contract are recognized as expenses. The Company does not have any significant financing components associated with its revenue contracts, as payment is received within one year. ● Commercial product and service contracts: Revenue is currently generated from multiple customers for research and development related services and small-volume orders. ● Government contracts: Revenue is principally generated under research and development contracts with agencies of the U.S. government or with prime contractors. These contracts may include cost reimbursement and fixed firm price terms. For the three and six months ended December 31, 2024, the Company was awarded two government contracts of $11,866,384 for providing services and delivering materials. The awards are firm fixed contracts that shall be paid upon completion of performance and recognized as revenue over an expected term of 36 months. For the three months ended December 31, 2024, the Company recognized its revenue of $1,612,519, of which $1,461,524 was from government contracts and $150,995 was from product sales for sampling purposes or development. For the six months ended December 31, 2024, the Company recognized its revenue of $2,093,254, of which $1,892,259 was from government contracts and $200,995 was from product sales for sampling purposes or development. As of December 31, 2024, the aggregate amount to remaining performance obligations for the government contracts was $10,664,948. Loss Per Share Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares outstanding plus potential dilutive common shares outstanding during the period. Potential dilutive securities, comprised of stock warrants and stock options, are not reflected in diluted loss per share because such shares are anti–dilutive. Dilutive impact of potential common shares resulting from common stock equivalents is determined by applying the treasury stock method. Stock-Based Compensation The Company accounts for stock-based compensation arrangements in accordance with guidance issued by the FASB, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, consultants, and directors based on estimated fair values. The Company estimates the fair value of stock-based compensation awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s consolidated statements of operations. The Company estimates the fair value of stock-based compensation awards using the Black-Scholes model. This model requires the Company to estimate the expected volatility and value of its common stock and the expected term of the stock options, all of which are highly complex and subjective variables. For employees and directors, the expected life was calculated based on the simplified method as described by the SEC Staff Accounting Bulletin No. 110, Share-Based Payment. For other service providers, the expected life was calculated using the contractual term of the award. The Company’s estimate of expected volatility was based on the volatility of peers. The Company has selected a risk-free rate based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the expected term of the options. The Company accounts for forfeitures upon occurrence. Income Taxes The Company is expected to have net operating loss carryforwards that it can use to offset a certain amount of taxable income in the future. The Company is currently analyzing the amount of loss carryforwards that will be available to reduce future taxable income. The resulting deferred tax assets will be offset by a valuation allowance due to the uncertainty of its realization. The primary difference between income tax expense attributable to continuing operations and the amount of income tax expense that would result from applying domestic federal statutory rates to income before income taxes relates to the recognition of a valuation allowance for deferred income tax assets. The Company has adopted FASB ASC 740-10, “ Income Taxes” The Company will file tax returns in the U.S. federal jurisdiction and the state of California. The Company’s federal and state return forms are subject to review by the taxing authorities. The Company is not currently under examination by any taxing authority, nor has it been notified of an impending examination. Recent Accounting Pronouncements The Company has evaluated all issued but not yet effective accounting pronouncements and determined that they are either immaterial or not relevant to the Company.

Convertible Notes

Convertible Notes	6 Months Ended
	Dec. 31, 2024
Convertible Notes [Abstract]
Convertible Notes	Note 3 – Convertible Notes Between August 5, 2024 and August 27, 2024, we issued convertible promissory notes in the aggregate principal amount of $3,145,000 to 10 accredited investors, pursuant to a private note financing. The Notes mature in June 2026 and do not carry any interest. The Notes are convertible into shares of the Company’s common stock par value $0.0001 per share (the “Common Stock”) upon the occurrence of certain events, (i.e., qualified financing resulting in at least $5,000,000 to the Company, if the Common Stock is uplisted to a national securities exchange or if neither of those such events occur prior to the maturity date, (together with Sale of the Company (as hereinafter defined), a “Conversion Event”)). In the event the Company does not complete qualified financing or uplist at or before the maturity date, the outstanding balance of the Notes shall automatically convert without any further action by the Holder into shares of the Company’s common stock equal to eighty-five percent (85%) to the VWAP of the Common Stock on the OTC Markets for the five trading days immediately prior to maturity date. The Note also provides that if there is a Sale of the Company, as defined in the Note, the Holder may elect to receive a cash payment equal to the aggregate amount of principal then outstanding under such Holder’s Note or convert the Note into shares of Common Stock equal to 85% of the VWAP of the Common Stock on the OTC Markets for the five trading days immediately prior to the Sale of the Company. Although the conversion price is dependent upon the type of Conversion Event that occurs, the Note does carry a ceiling and floor price: the applicable conversion price will not be lower than 85% of the 5-day VWAP on the applicable Closing Date (the “Floor Price”) nor will the applicable conversion price be higher than $3.50 per share (the “Ceiling Price”); the Floor Price and Ceiling Price shall automatically adjust in the event of a stock split or consolidation by the Company. Since the Floor Price is tied to the Closing Date, the Floor Price may be different for investors that are part of different closings. The Floor Price for the investors who participated in the closings is equal to $2.47 or $2.68 per share. The Investors were granted piggyback registration rights for the shares of Common Stock underlying the Note. The Note Purchase Agreement also contains customary representation and warranties of the Company and the Investors, indemnification obligations of the Company, termination provisions, and other obligations and rights of the parties. The Company analyzed the embedded features of the convertible notes and the debt discount is being amortized over the term of the convertible notes using the effective interest method and the derivative liabilities are marked-to-market at each reporting date. See Fair Value of Financial Instruments As of December 31, 2024, the Company’s convertible notes are as follows: Principal amounts of convertible notes $ 3,145,000 Less: unamortized debt discount (1,765,310 ) Convertible notes, net of discount $ 1,379,690

Stockholders_ Equity

Stockholders’ Equity	6 Months Ended
	Dec. 31, 2024
Stockholders’ Equity [Abstract]
Stockholders’ Equity	Note 4 – Stockholders’ Equity Authorized Shares The Company’s Articles of Incorporation authorize the issuance of two classes of shares of stock. The total number of shares which this corporation is authorized to issue is 50,000,000 shares of $0.0001 par value common stock and 10,000,000 of $0.0001 par value preferred stock. No Issued and Vested Shares to Officers On October 27, 2020, the Company issued 1,623,920 shares of common stock to Jonathan Klamkin, Director and Chief Executive Officer for $10,000. Initially 20% or 324,784 shares vested on October 27, 2020, and the remaining 1,299,136 shares vest in equal amounts, monthly over the subsequent 4 years. The stock purchase agreement contains a repurchase option whereby unvested shares may be repurchased by the Company, at the Company’s option. At December 31, 2024, all shares of Jonathan Klamkin vested. Registration Rights Agreement The Company entered into a registration rights agreement that provides for certain liquidated damages upon the occurrence of a “Registration Event,” which is defined as the occurrence of any of the following events: (a) the Company fails to file with the Commission the Registration Statement on or before the Registration Filing Date; (b) the Registration Statement is not declared effective by the Commission on or before the Registration Effectiveness Date; (c) after the SEC Effective Date, the Registration Statement ceases for any reason to remain effective or the Holders of Registrable Securities covered thereby are otherwise not permitted to utilize the prospectus therein to resell the Registrable Securities covered thereby, except for Blackout Periods permitted herein; or (d) following the listing or inclusion for quotation on an Approved Market, the Registrable Securities, if issued and outstanding, are not listed or included for quotation on an Approved Market, or trading of the Common Stock is suspended or halted on the Approved Market, which at the time constitutes the principal markets for the Common Stock, for more than three (3) full, consecutive Trading Days (other than as a result of (A) actions or inactions of parties other than the Company or its affiliates or of the Approved Market not reasonably in the control of the Company, or (B) suspension or halt of substantially all trading in equity securities (including the Common Stock) on the Approved Market). The maximum amount of liquidated damages that may be paid by the Company shall be an amount equal to eight percent (8%) of the shares covered by the registration rights agreement. This filing covered 11,010,002 shares. The Company currently expects to satisfy all of its obligations under the Registration Agreement and does not expect to pay any damages pursuant to this agreement; therefore, no liability has been recorded.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Dec. 31, 2024
Stock-Based Compensation [Abstract]
Stock-Based Compensation	Note 5 – Stock-Based Compensation Restricted Stock Awards In June 2021, the Company sold 723,008 shares of common stock to certain individuals in exchange for future management advisory services, for discounted prices price ranging from $.0104 to $.0195 per share. The shares are subject to restrictions that allow for repurchase of the shares by the Company due to a termination of the service agreement or other certain provisions. This repurchase right declines on a pro-rata basis over vesting periods (corresponding to the service period) ranging from 2-4 years. Related to these issuances, the Company has recorded deferred compensation of $1,372,435 for the value of the shares in excess of the purchase price paid by the advisors. The deferred compensation was expensed as consulting expense in the consolidated statements of operation over the service period. In March 2022, the Company signed an agreement to issue 150,000 shares of common stock valued at $300,000 to a consultant for providing consulting services to the Company for eighteen months. Related to these issuances, the Company has recorded deferred compensation of $300,000, which was expensed as consulting expense in the consolidated statements of operation over the eighteen months. For the three months ended December 31, 2024 and 2023, $6,981 have been amortized in the consolidated statements of operations and, for the six months ended December 31, 2024 and 2023, $13,962 and $18,938, respectively, have been amortized in the consolidated statements of operations. At December 31, 2024, $6,171 of deferred compensation included in the balance sheets is expected to be expensed within six months. The following is a schedule summarizing restricted stock awards for the periods indicated: December 31, 2024 Three Months Ended Six Months Ended Number of Weighted Number of Weighted Beginning balance 6,923 $ 1.90 10,597 $ 1.90 Issued - - - - Vested (3,674 ) 1.90 (7,348 ) 1.90 Forfeited - - - - Ending balance 3,249 $ 1.90 3,249 $ 1.90 December 31, 2023 Three Months Ended Six Months Ended Number of Weighted Number of Weighted Beginning balance 21,619 $ 1.90 75,293 $ 1.97 Issued - - - - Vested (3,675 ) 1.90 (57,349 ) 1.99 Forfeited - - - - Ending balance 17,944 $ 1.90 17,944 $ 1.90 Stock Options During the three months ended September 30, 2023, the Company issued 6,500 options to purchase common stock to consultants. The options expire in 10 years and have an exercise prices that range from $2.90 to $3.90 with immediate vesting. During the three months ended December 31, 2023, the Company issued 7,000 options to purchase common stock to a consultant. The options expire in 10 years and have an exercise price that ranges from $2.50 to $3.43 with immediate vesting. During the three months ended March 31, 2024, the Company issued 6,500 options to purchase common stock to consultants. The options expire in 10 years and have an exercise prices that range from $2.99 to $3.50 with immediate vesting. During the three months ended March 31, 2024, the Company issued 100,821 options to purchase common stock to the board of directors. The options expire in 10 years and vest in nine months with an exercise price of $2.99. During the three months ended September 30, 2024, the Company issued 12,000 options to purchase common stock to a consultant. The options expire in 10 years and have vest equally in twelve months with an exercise price of $3.13. During the three months ended December 31, 2024, the Company issued 54,000 options to purchase common stock to consultants. The options expire in 10 years and have an exercise prices that range from $2.97 to $3.51 with vesting periods from six months to two years. The Company estimates the fair value of each option award using the Black-Scholes option-pricing model. The Company used the following assumptions for to estimate the fair value of stock options for the period presented: Six Months Ended 2024 2023 Weighted-average fair value $ 1.89 $ 2.48 Expected volatility 113.9% - 122.4 % 104.9% - 106.6 % Expected term 1.0 years - 5.3 years 5.0 years - 6.2 years Dividend yield 0.00 % 0.00 % Risk-free interest rate 3.87% - 4.31 % 3.94% - 4.92 % For the three months ended December 31, 2024 and 2023, stock-based compensation expenses for options granted were $149,103 and $135,919, respectively. For the six months ended December 31, 2024 and 2023, stock-based compensation expenses for options granted were $316,194 and $376,496, respectively Unrecognized stock-based compensation expense was $620,570 and the average expected recognition period was 1.0 years as of December 31, 2024. The following is a schedule summarizing stock option activities for the periods presented: Three Months Ended Number of Weighted Aggregate (1) Outstanding at October 1, 2024 1,056,487 $ 2.42 $ 794,863 Granted 54,000 3.12 Exercised (155,666 ) 2.11 Expired/forfeited - - Outstanding at December 31, 2024 954,821 $ 2.51 $ 4,908,085 Exercisable at December 31, 2024 665,348 $ 2.44 $ 3,469,609 Outstanding at October 1, 2023 995,500 $ 2.33 $ 965,500 Granted 7,000 2.90 Exercised - - Expired/forfeited (41,375 ) 2.09 Outstanding at December 31, 2023 961,125 $ 2.35 $ 566,485 Exercisable at December 31, 2023 481,560 $ 2.20 $ 350,521 (1) Represents the excess of the fair value on the last day of period (which was $7.65 and $2.90 as of December 31, 2024 and 2023, respectively) over the exercise price, multiplied by the number of options. Six Months Ended Number of Weighted Aggregate (1) Outstanding at July 1, 2024 1,068,000 $ 2.41 $ 1,257,520 Granted 66,000 3.12 Exercised (155,666 ) 2.11 Expired/forfeited (23,959 ) 2.39 Outstanding at December 31, 2024 954,821 $ 2.51 $ 4,908,085 Exercisable at December 31, 2024 665,348 $ 2.44 $ 3,469,609 Outstanding at July 1, 2023 1,034,000 $ 2.31 $ 639,775 Granted 13,500 3.11 Exercised - - Expired/forfeited (86,375 ) 2.04 Outstanding at December 31, 2023 961,125 $ 2.35 $ 566,485 Exercisable at December 31, 2023 481,560 $ 2.20 $ 350,521 (1) Represents the excess of the fair value on the last day of period (which was $7.65 and $2.90 as of December 31, 2024 and 2023, respectively) over the exercise price, multiplied by the number of options.

Facility Operating Lease

Facility Operating Lease	6 Months Ended
	Dec. 31, 2024
Facility Operating Lease [Abstract]
Facility Operating Lease	Note 6 – Facility Operating Lease On April 1, 2021, the Company commenced a 5-year operating lease for a facility in Santa Barbara, California with total lease payments of $781,813. The Company determined the lease constitutes a Right of Use (ROU) asset and has recorded the present value of the lease payments as an asset and liability per ASC 842. The lease agreement waived the first three months of rent with payments commencing July 1, 2021. At the commencement of the lease, the net present value of the lease payments was $767,553. In addition to these lease payments, the Company is also responsible for its shares of common area operating expenses and electricity. Such expenses are considered variable costs and are not included in the measurement of the lease liability. The lease agreement also provides for the option to extend the lease for two additional sixty-month periods. On July 1, 2023, one of the two options to extend was considered reasonably certain of exercise and the Company remeasured the ROU asset and lease liability. The Company recorded the net present value of $1,189,606 for both the ROU asset and lease liability on July 1, 2023. The following table presents maturities of operating lease liabilities on an undiscounted basis as of December 31, 2024: For the years ending June 30, Remainder of 2025 $ 85,138 2026 173,454 2027 177,791 2028 182,235 2029 186,791 Thereafter 337,732 Total 1,143,141 Less imputed interest (136,405 ) Total lease liability 1,006,736 Less: lease liability, current portion 133,460 Lease liability, long term portion $ 873,276 The lease term and the discount rate for the lease at December 31, 2024 is 6.3 years and 4.00%, respectively. The total lease expenses were $41,441 and $49,344 for the three months ended December 31, 2024 and 2023, respectively, and $82,882 and $94,258 for the six months ended December 31, 2024 and 2023, respectively. The variable costs for common area operating expenses and electricity were $54,480 and $58,800 for the three months ended December 31, 2024 and 2023, respectively and $138,015 and $151,846 for the six months ended December 31, 2024 and 2023, respectively.

Warrants to Purchase Common Sto

Warrants to Purchase Common Stock	6 Months Ended
	Dec. 31, 2024
Warrants to Purchase Common Stock [Abstract]
Warrants to Purchase Common Stock	Note 7 – Warrants to Purchase Common Stock In connection with the Offering held from December 2022 through May 2023, the Company issued warrants of 85,653 to purchase common stock to the Placement Agents. The warrants carry a term of 5 years and an exercise price of $3.00. The following warrants to purchase common stock were outstanding as of December 31, 2024: Number of Shares Exercise Price Expiration Date 286,672 $ 2.00 June 22, 2026 37,433 2.00 June 28, 2026 11,500 2.00 July 1, 2026 27,032 3.00 December 22, 2027 4,588 3.00 January 10, 2028 6,720 3.00 March 31, 2028 44,933 3.00 May 10, 2028 418,878

Concentration of Credit Risk an

Concentration of Credit Risk and Significant Customers	6 Months Ended
	Dec. 31, 2024
Concentration of Credit Risk and Significant Customers [Abstract]
Concentration of Credit Risk and Significant Customers	Note 8 – Concentration of Credit Risk and Significant Customers The Company manages its credit risk associated with exposure to its direct customers on outstanding accounts receivable through the application of credit approvals and other monitoring procedures. The Company closely monitors the aging of accounts receivable from its direct customers. Significant customers are those that represent 10% or more of revenue or accounts receivable. Total revenues, by percentage, from individual customers representing 10% or more of total revenues in the respective periods were as follows: Three Months Ended December 31 Six Months Ended December 31, 2024 2023 2024 2023 Customer A * 46.8 % 11.4 % 41.6 % Customer B * 53.2 % * 47.4 % Customer C * * * * Customer D * * * * Customer E 76.2 % * 58.7 % * Customer F * * * 11.0 % Customer G * * * * * Less than 10% of total Accounts receivable, by percentage, from individual customers representing 10% or more of accounts receivable are set forth in the following table: As of December 31, 2024 June 30, Customer A * * Customer B * * Customer C * 18.3 % Customer D * 27.7 % Customer E 80.2 % * Customer F * * Customer G 11.4 % 53.9 % * Less than 10% of total Customer A, B, C, D and E are government agencies.

Subsequent Event

Subsequent Event	6 Months Ended
	Dec. 31, 2024
Subsequent Event [Abstract]
Subsequent Event	Note 9 – Subsequent Event The Company has evaluated subsequent events through the filing date or the issuance of these financial statements and is not aware of any material items that would require disclosure in the notes to the financial statements or would be required to be recognized as of December 31, 2024.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (2,894,824)	$ (1,128,520)	$ (3,624,443)	$ (2,610,829)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Dec. 31, 2024
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been presented in accordance with GAAP. The summary of significant accounting policies presented below is designed to assist in understanding the Company’s financial statements. Such financial statements and accompanying notes are the representations of the Company’s management, who is responsible for the Company’s integrity and objectivity. This Quarterly Report on Form 10-Q for the quarter ended December 31, 2024, should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended June 30, 2024. The accompanying consolidated financial statements and footnotes have been condensed and therefore do not contain all disclosures required by GAAP. The interim financial data are unaudited; however, in the opinion of Aeluma, Inc., the interim data include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Results for interim periods are not necessarily indicative of those to be expected for the full year.
Use of Estimates and Assumptions	Use of Estimates and Assumptions The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.
Reclassification of Prior Year Presentation	Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported consolidated financial statements.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers cash in banks, deposits in transit, and highly liquid debt instruments purchased with original maturities of three months or less to be cash and cash equivalents.
Concentration of Risk	Concentration of Risk The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company’s accounts are insured by the FDIC but at times may exceed federally insured limits.
Convertible Debt Instruments	Convertible Debt Instruments The Company evaluates agreements, including any convertible debt instruments to determine if those agreements or any embedded components of those agreements qualify as derivative financial instruments to be separately accounted for in accordance with FASB ASC Topic 815 Derivatives and Hedging 815”
Fair Value of Financial Instruments	Fair Value of Financial Instruments As defined in Financial Accounting Standards Board (“FASB”) ASC Topic No. 820, “Fair Value Measurements and Disclosures” (“ASC 820”), fair value is the price that would be received to sell an asset or paid to transfer the liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses the market or income approach. Based on this approach, the Company utilizes certain assumptions about the risk inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based on the observability of the inputs used in the valuation techniques, the Company is required to provide the following information according to the fair value hierarchy. The fair value hierarchy ranks the quality and the reliability of the information used to determine fair values. As a basis for considering these assumptions, ASC 820 defines a three-tier value hierarchy that prioritizes the inputs used in the valuation methodologies in measuring fair value. Level 1 – Unadjusted quoted prices in active, accessible market for identical assets or liabilities Level 2 – Other inputs that are directly or indirectly observable in the marketplace Level 3 – Unobservable inputs which are supported by little or no market activity The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The carrying values of the Company’s cash, accounts receivable, accounts payable, accrued expenses and other current liabilities approximate their fair value due to the relatively short maturity of these items. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. For recurring fair value measurement categorized within Level 3 assets and liabilities include those whose value is determined using market standard valuation technique described below. When observable inputs are not available, the market standard techniques for determining the estimated fair value of certain securities that trade infrequently, and therefore have little transparency, rely on inputs that are significant to the estimated fair value and that are not observable in the market or cannot be derived principally from or corroborated by observable market data. Management believes these inputs are based on assumptions deemed appropriate given the circumstances and consistent with what other market participants would use when pricing similar assets and liabilities. The Company’s embedded derivatives are classified in Level 3 using Black-Scholes option-pricing model since their values include significant unobservable inputs. The derivative liabilities are recognized at fair value on a recurring basis at December 31, 2024 and are Level 3 measurements. There have been no transfers between levels. Fair Value of Embedded Derivatives Beginning balance at July 1, 2024 $ - New derivative liabilities 2,193,129 Change in fair value of derivative liabilities 2,855,045 Ending balance at December 31, 2024 $ 5,048,174 The fair value of the embedded derivatives in our convertible notes at the balance sheet date were valued using the Black-Scholes option-pricing model with the following assumptions: December 31, Stock price $ 7.65 Expected volatility 128.3 % Expected term 1.5 years Dividend yield 0.00 % Risk-free interest rate 4.21 %
Property and Equipment	Property and Equipment Property, equipment and leasehold improvements are reported at historical cost, net of accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the less of the remaining lease term or the estimated useful life of the improvements. Repairs and maintenance to these assets are charged to expenses as incurred; major improvements enhancing the function and/or the asset’s useful life are capitalized. When items are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gains or losses arising from such transactions are recognized.
Intangible Assets	Intangible Assets Intangible assets are associated with the Aeluma.com domain name and are amortized on a straight-line basis over 10 years.
Revenue Recognition	Revenue Recognition The Company follows a five-step approach for recognizing revenue, consisting of the following: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to the performance obligations in the contract; and (5) recognizing revenue when, or as, the entity satisfies a performance obligation. Sales and other taxes the Company collects concurrent with revenue-producing activities are excluded from revenue. Incidental items that are immaterial in the context of the contract are recognized as expenses. The Company does not have any significant financing components associated with its revenue contracts, as payment is received within one year. ● Commercial product and service contracts: Revenue is currently generated from multiple customers for research and development related services and small-volume orders. ● Government contracts: Revenue is principally generated under research and development contracts with agencies of the U.S. government or with prime contractors. These contracts may include cost reimbursement and fixed firm price terms. For the three and six months ended December 31, 2024, the Company was awarded two government contracts of $11,866,384 for providing services and delivering materials. The awards are firm fixed contracts that shall be paid upon completion of performance and recognized as revenue over an expected term of 36 months. For the three months ended December 31, 2024, the Company recognized its revenue of $1,612,519, of which $1,461,524 was from government contracts and $150,995 was from product sales for sampling purposes or development. For the six months ended December 31, 2024, the Company recognized its revenue of $2,093,254, of which $1,892,259 was from government contracts and $200,995 was from product sales for sampling purposes or development. As of December 31, 2024, the aggregate amount to remaining performance obligations for the government contracts was $10,664,948.
Loss Per Share	Loss Per Share Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares outstanding plus potential dilutive common shares outstanding during the period. Potential dilutive securities, comprised of stock warrants and stock options, are not reflected in diluted loss per share because such shares are anti–dilutive. Dilutive impact of potential common shares resulting from common stock equivalents is determined by applying the treasury stock method.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation arrangements in accordance with guidance issued by the FASB, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, consultants, and directors based on estimated fair values. The Company estimates the fair value of stock-based compensation awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s consolidated statements of operations. The Company estimates the fair value of stock-based compensation awards using the Black-Scholes model. This model requires the Company to estimate the expected volatility and value of its common stock and the expected term of the stock options, all of which are highly complex and subjective variables. For employees and directors, the expected life was calculated based on the simplified method as described by the SEC Staff Accounting Bulletin No. 110, Share-Based Payment. For other service providers, the expected life was calculated using the contractual term of the award. The Company’s estimate of expected volatility was based on the volatility of peers. The Company has selected a risk-free rate based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the expected term of the options. The Company accounts for forfeitures upon occurrence.
Income Taxes	Income Taxes The Company is expected to have net operating loss carryforwards that it can use to offset a certain amount of taxable income in the future. The Company is currently analyzing the amount of loss carryforwards that will be available to reduce future taxable income. The resulting deferred tax assets will be offset by a valuation allowance due to the uncertainty of its realization. The primary difference between income tax expense attributable to continuing operations and the amount of income tax expense that would result from applying domestic federal statutory rates to income before income taxes relates to the recognition of a valuation allowance for deferred income tax assets. The Company has adopted FASB ASC 740-10, “ Income Taxes” The Company will file tax returns in the U.S. federal jurisdiction and the state of California. The Company’s federal and state return forms are subject to review by the taxing authorities. The Company is not currently under examination by any taxing authority, nor has it been notified of an impending examination.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company has evaluated all issued but not yet effective accounting pronouncements and determined that they are either immaterial or not relevant to the Company.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Dec. 31, 2024
Summary of Significant Accounting Policies [Abstract]
Schedule of Derivative Liabilities	The derivative liabilities are recognized at fair value on a recurring basis at December 31, 2024 and are Level 3 measurements. There have been no transfers between levels. Fair Value of Embedded Derivatives Beginning balance at July 1, 2024 $ - New derivative liabilities 2,193,129 Change in fair value of derivative liabilities 2,855,045 Ending balance at December 31, 2024 $ 5,048,174
Schedule of Black-Scholes Option-Pricing	The fair value of the embedded derivatives in our convertible notes at the balance sheet date were valued using the Black-Scholes option-pricing model with the following assumptions: December 31, Stock price $ 7.65 Expected volatility 128.3 % Expected term 1.5 years Dividend yield 0.00 % Risk-free interest rate 4.21 %

Convertible Notes (Tables)

Convertible Notes (Tables)	6 Months Ended
	Dec. 31, 2024
Convertible Notes [Abstract]
Schedule of Convertible Notes	As of December 31, 2024, the Company’s convertible notes are as follows: Principal amounts of convertible notes $ 3,145,000 Less: unamortized debt discount (1,765,310 ) Convertible notes, net of discount $ 1,379,690

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Dec. 31, 2024
Stock-Based Compensation [Abstract]
Schedule of Restricted Stock Awards	The following is a schedule summarizing restricted stock awards for the periods indicated: December 31, 2024 Three Months Ended Six Months Ended Number of Weighted Number of Weighted Beginning balance 6,923 $ 1.90 10,597 $ 1.90 Issued - - - - Vested (3,674 ) 1.90 (7,348 ) 1.90 Forfeited - - - - Ending balance 3,249 $ 1.90 3,249 $ 1.90 December 31, 2023 Three Months Ended Six Months Ended Number of Weighted Number of Weighted Beginning balance 21,619 $ 1.90 75,293 $ 1.97 Issued - - - - Vested (3,675 ) 1.90 (57,349 ) 1.99 Forfeited - - - - Ending balance 17,944 $ 1.90 17,944 $ 1.90
Schedule of Estimates Fair Value of Each Option Award	The Company estimates the fair value of each option award using the Black-Scholes option-pricing model. The Company used the following assumptions for to estimate the fair value of stock options for the period presented: Six Months Ended 2024 2023 Weighted-average fair value $ 1.89 $ 2.48 Expected volatility 113.9% - 122.4 % 104.9% - 106.6 % Expected term 1.0 years - 5.3 years 5.0 years - 6.2 years Dividend yield 0.00 % 0.00 % Risk-free interest rate 3.87% - 4.31 % 3.94% - 4.92 %
Schedule of Stock Option Activity	The following is a schedule summarizing stock option activities for the periods presented: Number of Weighted Aggregate (1) Outstanding at October 1, 2024 1,056,487 $ 2.42 $ 794,863 Granted 54,000 3.12 Exercised (155,666 ) 2.11 Expired/forfeited - - Outstanding at December 31, 2024 954,821 $ 2.51 $ 4,908,085 Exercisable at December 31, 2024 665,348 $ 2.44 $ 3,469,609 Outstanding at October 1, 2023 995,500 $ 2.33 $ 965,500 Granted 7,000 2.90 Exercised - - Expired/forfeited (41,375 ) 2.09 Outstanding at December 31, 2023 961,125 $ 2.35 $ 566,485 Exercisable at December 31, 2023 481,560 $ 2.20 $ 350,521 (1) Represents the excess of the fair value on the last day of period (which was $7.65 and $2.90 as of December 31, 2024 and 2023, respectively) over the exercise price, multiplied by the number of options. Number of Weighted Aggregate (1) Outstanding at July 1, 2024 1,068,000 $ 2.41 $ 1,257,520 Granted 66,000 3.12 Exercised (155,666 ) 2.11 Expired/forfeited (23,959 ) 2.39 Outstanding at December 31, 2024 954,821 $ 2.51 $ 4,908,085 Exercisable at December 31, 2024 665,348 $ 2.44 $ 3,469,609 Outstanding at July 1, 2023 1,034,000 $ 2.31 $ 639,775 Granted 13,500 3.11 Exercised - - Expired/forfeited (86,375 ) 2.04 Outstanding at December 31, 2023 961,125 $ 2.35 $ 566,485 Exercisable at December 31, 2023 481,560 $ 2.20 $ 350,521 (1) Represents the excess of the fair value on the last day of period (which was $7.65 and $2.90 as of December 31, 2024 and 2023, respectively) over the exercise price, multiplied by the number of options.

Facility Operating Lease (Table

Facility Operating Lease (Tables)	6 Months Ended
	Dec. 31, 2024
Facility Operating Lease [Abstract]
Schedule of Maturities of Operating Lease Liabilities	The following table presents maturities of operating lease liabilities on an undiscounted basis as of December 31, 2024: For the years ending June 30, Remainder of 2025 $ 85,138 2026 173,454 2027 177,791 2028 182,235 2029 186,791 Thereafter 337,732 Total 1,143,141 Less imputed interest (136,405 ) Total lease liability 1,006,736 Less: lease liability, current portion 133,460 Lease liability, long term portion $ 873,276

Warrants to Purchase Common S_2

Warrants to Purchase Common Stock (Tables)	6 Months Ended
	Dec. 31, 2024
Warrants to Purchase Common Stock [Abstract]
Schedule of Warrants to Purchase Common Stock	The following warrants to purchase common stock were outstanding as of December 31, 2024: Number of Shares Exercise Price Expiration Date 286,672 $ 2.00 June 22, 2026 37,433 2.00 June 28, 2026 11,500 2.00 July 1, 2026 27,032 3.00 December 22, 2027 4,588 3.00 January 10, 2028 6,720 3.00 March 31, 2028 44,933 3.00 May 10, 2028 418,878

Concentration of Credit Risk _2

Concentration of Credit Risk and Significant Customers (Tables)	6 Months Ended
	Dec. 31, 2024
Concentration of Credit Risk and Significant Customers [Abstract]
Schedule of Concentration Risk Percentage	Total revenues, by percentage, from individual customers representing 10% or more of total revenues in the respective periods were as follows: Three Months Ended December 31 Six Months Ended December 31, 2024 2023 2024 2023 Customer A * 46.8 % 11.4 % 41.6 % Customer B * 53.2 % * 47.4 % Customer C * * * * Customer D * * * * Customer E 76.2 % * 58.7 % * Customer F * * * 11.0 % Customer G * * * * * Less than 10% of total Accounts receivable, by percentage, from individual customers representing 10% or more of accounts receivable are set forth in the following table: As of December 31, 2024 June 30, Customer A * * Customer B * * Customer C * 18.3 % Customer D * 27.7 % Customer E 80.2 % * Customer F * * Customer G 11.4 % 53.9 % * Less than 10% of total

The Company (Details)

The Company (Details)	3 Months Ended		6 Months Ended
	Dec. 31, 2024 USD ($) ft²	Dec. 31, 2023 USD ($)	Dec. 31, 2024 USD ($) ft²	Dec. 31, 2023 USD ($)	Jun. 30, 2024 USD ($)
The Company [Abstract]
Area of manufacturing cleanroom (in Square Feet) | ft²	9,000		9,000
Incurred net loss	$ (2,894,824)	$ (1,128,520)	$ (3,624,443)	$ (2,610,829)
Accumulated deficit	$ (17,248,804)		$ (17,248,804)		$ (13,624,361)

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Summary of Significant Accounting Policies [Line Items]
Amortized on a straight-line basis	10 years		10 years
Services and delivering materials			$ 11,866,384
Revenue	$ 1,612,519	$ 262,992	2,093,254	$ 295,392
Interest and penalties			0
Materials [Member]
Summary of Significant Accounting Policies [Line Items]
Government contracts			2
Government Contracts [Member]
Summary of Significant Accounting Policies [Line Items]
Revenue	1,461,524		1,892,259
Revenue from remaining performance obligations	10,664,948		10,664,948
Purposes or Development [Member]
Summary of Significant Accounting Policies [Line Items]
Revenue	$ 150,995		$ 200,995

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Schedule of Derivative Liabilities (Details) - USD ($)	6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Schedule of Derivative Liabilities [Abstract]
Beginning balance at July 1, 2024
New derivative liabilities	2,193,129
Change in fair value of derivative liabilities	2,855,045
Ending balance at December 31, 2024	$ 5,048,174

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Black-Scholes Option-Pricing (Details)	Dec. 31, 2024
Stock price [Member]
Schedule of Black-Scholes Option-Pricing [Line Items]
Fair value of embedded derivatives	7.65
Expected volatility [Member]
Schedule of Black-Scholes Option-Pricing [Line Items]
Fair value of embedded derivatives	128.3
Expected term [Member]
Schedule of Black-Scholes Option-Pricing [Line Items]
Fair value of embedded derivatives	1.5
Dividend yield [Member]
Schedule of Black-Scholes Option-Pricing [Line Items]
Fair value of embedded derivatives	0
Risk-free interest rate [Member]
Schedule of Black-Scholes Option-Pricing [Line Items]
Fair value of embedded derivatives	4.21

Convertible Notes (Details)

Convertible Notes (Details) - USD ($)	6 Months Ended
	Dec. 31, 2024	Aug. 27, 2024	Jun. 30, 2024
Convertible Notes [Line Items]
Aggregate principal amount (in Dollars)		$ 3,145,000
Common stock, par value	$ 0.0001		$ 0.0001
Conversion price percentage	85%
Conversion price per share	$ 3.5
VWAP [Member]
Convertible Notes [Line Items]
Value weighted average price percentage	85%
Minimum [Member] | Floor Price [Member]
Convertible Notes [Line Items]
Initial closing equal per share	$ 2.47
Maximum [Member] | Floor Price [Member]
Convertible Notes [Line Items]
Initial closing equal per share	$ 2.68
Common Stock [Member]
Convertible Notes [Line Items]
Qualified financing least (in Dollars)	$ 5,000,000
Value weighted average price percentage	85%

Convertible Notes - Schedule of

Convertible Notes - Schedule of Convertible Notes (Details)	Dec. 31, 2024 USD ($)
Schedule of Convertible Notes [Abstract]
Principal amounts of convertible notes	$ 3,145,000
Less: unamortized debt discount	(1,765,310)
Convertible notes, net of discount	$ 1,379,690

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - USD ($)		6 Months Ended
	Oct. 27, 2020	Dec. 31, 2024	Jun. 30, 2024
Stockholders’ Equity [Line Items]
Common stock, shares authorized		50,000,000	50,000,000
Common stock, per share (in Dollars per share)		$ 0.0001	$ 0.0001
Preferred stock, shares authorized		10,000,000	10,000,000
Preferred stock, par value (in Dollars per share)		$ 0.0001	$ 0.0001
Preferred shares issued
Shares percentage	20%
Vested shares	324,784
Agreement percentage		8%
Covered shares		11,010,002
Jonathan Klamkin [Member]
Stockholders’ Equity [Line Items]
Shares issued	1,623,920
Director [Member]
Stockholders’ Equity [Line Items]
Shares issued value (in Dollars)	$ 10,000
Chief Executive Officer [Member]
Stockholders’ Equity [Line Items]
Shares issued value (in Dollars)	$ 10,000
Vest [Member]
Stockholders’ Equity [Line Items]
Vested shares	1,299,136
Vested shares monthly amount	4 years

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($)	1 Months Ended		3 Months Ended					6 Months Ended
	Mar. 31, 2022	Jun. 30, 2021	Dec. 31, 2024	Sep. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2024	Dec. 31, 2023
Stock-Based Compensation [Line Items]
Deferred compensation (in Dollars)	$ 300,000							$ 1,372,435
Amortized cost (in Dollars)			$ 6,981			$ 6,981		13,962	$ 18,938
Deferred compensation (in Dollars)			6,171					6,171
Stock-based compensation expenses (in Dollars)			149,103			$ 135,919		316,194	$ 376,496
Unrecognized stock-based compensation (in Dollars)			$ 620,570					$ 620,570
Average expected recognition period								1 year
Excess of fair value price per share								$ 7.65	$ 2.9
Restricted Stock Awards [Member]
Stock-Based Compensation [Line Items]
Sale of common stock (in Shares)		723,008
Minimum [Member]
Stock-Based Compensation [Line Items]
Excess of fair value price per share		$ 0.0104
Vesting terms			2 years					2 years
Maximum [Member]
Stock-Based Compensation [Line Items]
Excess of fair value price per share		$ 0.0195
Vesting terms			6 years					4 years
Consultant [Member]
Stock-Based Compensation [Line Items]
Issue of share (in Shares)	150,000
Common stock value (in Dollars)	$ 300,000
Number of shares issued (in Shares)			54,000	12,000	6,500	7,000	6,500
Expiring period			10 years	10 years	10 years	10 years	10 years
Exercise price increase per share				$ 3.13
Consultant [Member] | Minimum [Member]
Stock-Based Compensation [Line Items]
Exercise price decrease per share			$ 2.97		$ 2.99	$ 2.5	$ 2.9
Consultant [Member] | Maximum [Member]
Stock-Based Compensation [Line Items]
Exercise price increase per share			$ 3.51		$ 3.5	$ 3.43	$ 3.9
Employees [Member]
Stock-Based Compensation [Line Items]
Number of shares issued (in Shares)					100,821
Expiring period					10 years
Exercise price decrease per share					$ 2.99

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Restricted Stock Awards (Details) - Restricted Stock [Member] - $ / shares	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Schedule of Restricted Stock Awards [Line Items]
Number of Shares, Beginning balance	6,923	21,619	10,597	75,293
Weighted Average Grant Date Fair Value per Price, Outstanding beginning balance	$ 1.9	$ 1.9	$ 1.9	$ 1.97
Number of Shares, Issued
Weighted Average Grant Date Fair Value per Price, Issued
Number of Shares, Vested	(3,674)	(3,675)	(7,348)	(57,349)
Weighted Average Grant Date Fair Value per Price, Vested	$ 1.9	$ 1.9	$ 1.9	$ 1.99
Number of Shares, Forfeited
Weighted Average Grant Date Fair Value per Price, Forfeited
Number of Shares, Ending balance	3,249	17,944	3,249	17,944
Weighted Average Grant Date Fair Value per Price, Ending balance	$ 1.9	$ 1.9	$ 1.9	$ 1.9

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Estimates Fair Value of Each Option Award (Details) - $ / shares	6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Schedule of Estimates Fair Value of Each Option Award [Line Items]
Weighted-average fair value (in Dollars per share)	$ 1.89	$ 2.48
Dividend yield	0%	0%
Minimum [Member]
Schedule of Estimates Fair Value of Each Option Award [Line Items]
Expected volatility	113.90%	104.90%
Expected term	1 year	5 years
Risk-free interest rate	3.87%	3.94%
Maximum [Member]
Schedule of Estimates Fair Value of Each Option Award [Line Items]
Expected volatility	122.40%	106.60%
Expected term	5 years 3 months 18 days	6 years 2 months 12 days
Risk-free interest rate	4.31%	4.92%

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule of Stock Option Activity (Details) - USD ($)		3 Months Ended		6 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Schedule of Stock Option Activity [Abstract]
Number of Options, Beginning balance		1,056,487	995,500	1,068,000	1,034,000
Weighted Average Exercise Price, Beginning balance		$ 2.42	$ 2.33	$ 2.41	$ 2.31
Aggregate Intrinsic Value, Beginning balance	[1]	$ 794,863	$ 965,500	$ 1,257,520	$ 639,775
Number of Options, Granted		54,000	7,000	66,000	13,500
Weighted Average Exercise Price, Granted		$ 3.12	$ 2.9	$ 3.12	$ 3.11
Number of Options, Exercised		(155,666)		(155,666)
Weighted Average Exercise Price, Exercised		$ 2.11		$ 2.11
Number of Options, Expired/cancelled			(41,375)	(23,959)	(86,375)
Weighted Average Exercise Price, Expired/cancelled			$ 2.09	$ 2.39	$ 2.04
Number of Options, Ending balance		954,821	961,125	954,821	961,125
Weighted Average Exercise Price, Ending balance		$ 2.51	$ 2.35	$ 2.51	$ 2.35
Aggregate Intrinsic Value, Ending balance	[1]	$ 4,908,085	$ 566,485	$ 4,908,085	$ 566,485
Number of Options, Exercisable		665,348	481,560	665,348	481,560
Weighted Average Exercise Price, Exercisable		$ 2.44	$ 2.2	$ 2.44	$ 2.2
Aggregate Intrinsic Value, Exercisable	[1]	$ 3,469,609	$ 350,521	$ 3,469,609	$ 350,521
[1] Represents the excess of the fair value on the last day of period (which was $7.65 and $2.90 as of December 31, 2024 and 2023, respectively) over the exercise price, multiplied by the number of options.

Facility Operating Lease (Detai

Facility Operating Lease (Details) - USD ($)			3 Months Ended		6 Months Ended
	Jul. 01, 2023	Apr. 01, 2021	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Facility Operating Lease [Abstract]
Operating lease term of contract		5 years
Total lease expenses		$ 781,813	$ 41,441	$ 49,344	$ 82,882	$ 94,258
Lease payments					$ 767,553
Net present value	$ 1,189,606
Operating lease term			6 years 3 months 18 days		6 years 3 months 18 days
Operating lease discount rate			4%		4%
Operating expenses			$ 54,480	$ 58,800	$ 138,015	$ 151,846

Facility Operating Lease - Sche

Facility Operating Lease - Schedule of Maturities of Operating Lease Liabilities (Details) - USD ($)	Dec. 31, 2024	Jun. 30, 2024
Schedule of Maturities of Operating Lease Liabilities [Abstract]
Remainder of 2025	$ 85,138
2026	173,454
2027	177,791
2028	182,235
2029	186,791
Thereafter	337,732
Total	1,143,141
Less imputed interest	(136,405)
Total lease liability	1,006,736
Less: lease liability, current portion	133,460	$ 128,743
Lease liability, long term portion	$ 873,276	$ 941,200

Warrants to Purchase Common S_3

Warrants to Purchase Common Stock (Details) - $ / shares	Dec. 31, 2024	May 31, 2023
Warrants to Purchase Common Stock [Line Items]
Issued warrants		85,653
Warrant term	5 years
Warrant [Member]
Warrants to Purchase Common Stock [Line Items]
Exercise price	$ 3

Warrants to Purchase Common S_4

Warrants to Purchase Common Stock - Schedule of Warrants to Purchase Common Stock (Details)	Dec. 31, 2024 $ / shares shares
Schedule of Warrants to Purchase Common Stock [Line Items]
Number of Shares	418,878
Exercise Price 2.00 One [Member]
Schedule of Warrants to Purchase Common Stock [Line Items]
Number of Shares	286,672
Exercise Price (in Dollars per share) | $ / shares	$ 2
Expiration Date	Jun. 22, 2026
Exercise Price 2.00 Two [Member]
Schedule of Warrants to Purchase Common Stock [Line Items]
Number of Shares	37,433
Exercise Price (in Dollars per share) | $ / shares	$ 2
Expiration Date	Jun. 28, 2026
Exercise Price 2.00 Three [Member]
Schedule of Warrants to Purchase Common Stock [Line Items]
Number of Shares	11,500
Exercise Price (in Dollars per share) | $ / shares	$ 2
Expiration Date	Jul. 01, 2026
Exercise Price 3.00 One [Member]
Schedule of Warrants to Purchase Common Stock [Line Items]
Number of Shares	27,032
Exercise Price (in Dollars per share) | $ / shares	$ 3
Expiration Date	Dec. 22, 2027
Exercise Price 3.00 Two [Member]
Schedule of Warrants to Purchase Common Stock [Line Items]
Number of Shares	4,588
Exercise Price (in Dollars per share) | $ / shares	$ 3
Expiration Date	Jan. 10, 2028
Exercise Price 3.00 Three [Member]
Schedule of Warrants to Purchase Common Stock [Line Items]
Number of Shares	6,720
Exercise Price (in Dollars per share) | $ / shares	$ 3
Expiration Date	Mar. 31, 2028
Exercise Price 3.00 Four [Member]
Schedule of Warrants to Purchase Common Stock [Line Items]
Number of Shares	44,933
Exercise Price (in Dollars per share) | $ / shares	$ 3
Expiration Date	May 10, 2028

Concentration of Credit Risk _3

Concentration of Credit Risk and Significant Customers - Schedule of Concentration Risk Percentage (Details) - Customer Concentration Risk [Member]		3 Months Ended				6 Months Ended				12 Months Ended
		Dec. 31, 2024		Dec. 31, 2023		Dec. 31, 2024		Dec. 31, 2023		Jun. 30, 2023
Customer A [Member] | Revenue Benchmark [Member]
Concentration Risk [Line Items]
Customer			[1]	46.80%		11.40%		41.60%
Customer A [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Customer	[1]
Customer B [Member] | Revenue Benchmark [Member]
Concentration Risk [Line Items]
Customer			[1]	53.20%			[1]	47.40%
Customer B [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Customer	[1]
Customer C [Member] | Revenue Benchmark [Member]
Concentration Risk [Line Items]
Customer	[1]
Customer C [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Customer							[1]			18.30%
Customer D [Member] | Revenue Benchmark [Member]
Concentration Risk [Line Items]
Customer	[1]
Customer D [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Customer							[1]			27.70%
Customer E [Member] | Revenue Benchmark [Member]
Concentration Risk [Line Items]
Customer		76.20%			[1]	58.70%			[1]
Customer E [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Customer						80.20%					[1]
Customer F [Member] | Revenue Benchmark [Member]
Concentration Risk [Line Items]
Customer			[1]		[1]		[1]	11%
Customer F [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Customer	[1]
Customer G [Member] | Revenue Benchmark [Member]
Concentration Risk [Line Items]
Customer	[1]
Customer G [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Customer						11.40%				53.90%
[1] Less than 10% of total